The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages.
OBJECTIVE
We measured efflux from macrophages to apolipoprotein B-depleted serum from 263 specimens and found instances in which serum having similar high-density lipoprotein cholesterol (HDL-C) differed in their efflux capacity. Thus, we wanted to elucidate why efflux capacity could be independent of total HDL-C or apolipoprotein A-I (apoA-I).


RESULTS
To understand why sera with similar HDL-C or apoA-I could differ in total efflux capacity, we assessed their ability to promote efflux via the pathways expressed in cAMP-treated J774 macrophages. Briefly, macrophages were preincubated with probucol to block ABCA1, with BLT-1 to block SR-BI, and with both inhibitors to measure residual efflux. ABCG1 efflux was measured with transfected BHK-1 cells. We used apolipoprotein B-depleted serum from specimens with similar HDL-C values at the 25(th) and 75(th) percentiles. Specimens in each group were classified as having high or low efflux based on total efflux being above or below the group average. We found that independently of HDL-C, sera with higher efflux capacity had a significant increase in ABCA1-mediated efflux, which was significantly correlated to the concentration of pre beta-1 HDL. The same result was obtained when these sera were similarly analyzed based on similar apoA-I.


CONCLUSIONS
Sera with similar HDL-C or apoA-I differ in their ability to promote macrophage efflux because of differences in the concentration of pre beta-1 HDL.
de la Llera-Moya
Margarita
M
Division of Gastroenterology, Hepatology and Nutrition, The Children's Hospital of Philadelphia, 3615 Civic Center Blvd, Philadelphia, PA 19104, USA. moya@email.chop.edu
Drazul-Schrader
Denise
D
Asztalos
Bela F
BF
Cuchel
Marina
M
Rader
Daniel J
DJ
Rothblat
George H
GH
D064286:ATP Binding Cassette Transporter 1; D018528:ATP-Binding Cassette Transporters / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000818:Animals; D016632:Apolipoprotein A-I / Q000097:blood; D001055:Apolipoproteins B / Q000172:deficiency; D001692:Biological Transport; D002460:Cell Line; D008076:Cholesterol, HDL / Q000097:blood*; D000242:Cyclic AMP / Q000378:metabolism; D003517:Cyclopentanes / Q000494:pharmacology; D005260:Female; D053442:High-Density Lipoproteins, Pre-beta / Q000097:blood; D006801:Humans; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D051379:Mice; D008875:Middle Aged; D011341:Probucol / Q000494:pharmacology; D011446:Prospective Studies; D051122:Scavenger Receptors, Class B / Q000037:antagonists & inhibitors / Q000378:metabolism; D013882:Thiosemicarbazones / Q000494:pharmacology; D014162:Transfection
C526651:2-hexyl-1-cyclopentanone thiosemicarbazone; C577836:ABCA1 protein, human; C505693:APOA1 protein, human; D064286:ATP Binding Cassette Transporter 1; D018528:ATP-Binding Cassette Transporters; D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D003517:Cyclopentanes; D053442:High-Density Lipoproteins, Pre-beta; C454739:Scarb1 protein, mouse; D051122:Scavenger Receptors, Class B; D013882:Thiosemicarbazones; D000242:Cyclic AMP; D011341:Probucol